Remdesivir

Overview

4.4 out of 5 (17 Reviews)

Credits

1.00

Post Assessment Questions

5

Start Date

1 Jan 2021

Last Review Date

28 Feb 2024

Expiration Date

31 Dec 2023

Estimated Time To Finish

60 Minutes


 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Remdesivir is a broad-spectrum antiviral agent that has showcased its efficacy against a spectrum of viruses, including filoviruses (eg, Ebola, Marburg), coronaviruses (eg, SARS-CoV, MERS-CoV, SARS-CoV-2), paramyxoviruses (eg, parainfluenza type III, Nipah, Hendra, measles, mumps), and Pnemoviridae (eg, respiratory syncytial virus). In vitro studies have demonstrated its antiviral activity against SARS-CoV-2, prompting its consideration as an investigational drug early in the pandemic. Following randomized clinical trials affirming superior clinical efficacy compared to placebo, remdesivir was the first antiviral drug approved by the US Food and Drug Administration (FDA). This approval signifies its role in the clinical management of patients with severe suspected or laboratory-confirmed COVID-19. This activity meticulously explores remdesivir's pharmacology, dosing, indications, contraindications, and potential adverse events to enhance patient outcomes.


Target Audience

This activity has been designed to meet the educational needs of physicians.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Identify appropriate candidates for remdesivir therapy based on clinical criteria, such as severe COVID-19 infection and specific patient characteristics.

  • Apply knowledge of the current clinical evidence and guidelines to determine the optimal timing and duration of remdesivir therapy for individual patients.

  • Assess treatment response and monitor patients for potential adverse effects, such as liver function abnormalities, renal impairment, and infusion-related reactions.

  • Develop collaboration with infectious disease specialists, pharmacists, and other healthcare professionals to ensure coordinated care, address any challenges, and optimize the use of remdesivir.

Disclosures

The Campbell University Jerry M. Wallace School of Osteopathic Medicine (CUSOM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they or their immediate family may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CUSOM for resolution, to ensure fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

CUSOM will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for authors, editors, planners, peer reviewers, and/or relevant staff is provided with this activity.

Continuing Education Accreditation Information

 

 

The Campbell University Jerry M. Wallace School of Osteopathic Medicine (CUSOM) is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. CUSOM designates this enduring material for a maximum of 1.00 AOA Category 1 B Credits and will report CME credits commensurate with the extent of the physician's participation in the activity.

Cancellation Policy: Cancellations must be received in writing and a money back guarantee is provided if not completely satisfied.

  • StatPearls and CUSOM reserve the right to cancel any course due to unforeseen circumstances. StatPearls and CUSOM will not be responsible for other expenses incurred by the participant in the unlikely event that the program is canceled.

Equal Opportunity

  • StatPearls and CUSOM are Equal Opportunity / Affirmative Action / Equal Access Institutions. 

Medium or Media Used:

  • Computer Requirements:  Internet Access
  • E-mail Address

Instructions for Credit

  1. Register for the activity and create a StatPearls login.     
  2. Review the required accreditation information:  Target audience, learning objectives and disclosure information.
  3. Complete the entire self-study activity.
  4. Complete the post-test assessments.
  5. Successfully pass the post-test with a minimum score of 100%.
  6. Complete the evaluation form.
  7. Obtain a certificate.

StatPearls and CUSOM adheres to AOA Standards regarding commercial support of continuing medical education. It is the policy of StatPearls and Campbell that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that authors and editors will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation. Detailed disclosure will be made prior to starting the activity.

The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

This course is intended for osteopathic physicians who wish to earn AOA CME credit. Take this version of the course to ensure you receive appropriate credit.

 

 
 

Reviews

Rana M. on 3/11/2021

Scott D. on 4/4/2021

Laura C. on 5/15/2021

Kelsey G. on 8/1/2021

Mary S. on 8/3/2021

Roshni J. on 9/18/2021

Erika G. on 12/31/2021

Travis V. on 1/3/2022

Peter S. on 4/8/2022

Christine G. on 8/30/2022

Kelly D. on 10/27/2022

Mark O. on 12/20/2022

Shon R. on 4/27/2023

“started ASAP” is too casual. “Remdesiivr has demonstrated” – ah, the drug that this CE is about is not spelled correctly. “insomnia,multi-organ dysfunction,” – there should be a period after a coma. A very small percentage of patients receiving remdesivir have cardiac side effects which are easily managed by slowing the infusion rate. This information should be added. Having said that, there may not be a published article that discusses how to manage that side effect. I should add that a CE about a drug that is relatively new and widely used is not easy to write as the CE's content is quickly outdated. So, there is no criticism meant.

john e. on 5/22/2023

Christine G. on 6/3/2023

Kimberley R. on 6/7/2023

Kim L. on 1/8/2024

Unlimited Physician CME

Stay up to date on the latest medical knowledge with 6673 CME activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7923.5 hours of CME.

Learn About Lifetime CME

Single Activity

Take this single activity

$39 1 activity

6 Month Unlimited Physician CME

Access to all the Unlimited Physician CME activities in all specialties.

$399 per half year per user

1 Year Unlimited Physician CME

Access to all the Unlimited Physician CME activities in all specialties.

$599 per 1 year per user